| DC9375 |
GPDA
Featured
|
GPDA(Glycylproline p-nitroanilide tosylate) is the substarate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay. |
|
| DC7137 |
Filgotinib(GLPG0634)
Featured
|
Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease. |
|
| DC8593 |
GPR120 Compound A
Featured
|
GPR120 compound A is an orally available, high-affinity agonist of GPR120 (EC50 = ~0.35 µm) that demonstrates potent selectivity over another lipid-sensing G-protein, GPR40 (FFAR1). |
|
| DC8206 |
GPR39-C3
Featured
|
GPR39-C3 is the first potent, selective and orally bioavailable GPR39 agonist with an EC50 ~0.8 nM for human GPR39 and ~0.4 nM for rodent GPR39. |
|
| DC20076 |
GPR4 antagonist 3(NE 52-QQ57 )
Featured
|
GPR4 antagonist 3 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. Anti-inflammatory activities. |
|
| DC26114 |
GpTx-1
Featured
|
GpTx-1 is a potent, selective, 34-residue peptide antagonist of Nav1.7 sodium channel with IC50 of 10 nM, displays 20- and 1000- fold selectivity over NaV1.4 and NaV1.5.. |
|
| DC21064 |
GR-127935 hydrochloride
Featured
|
GR-127935 potent and selective 5-HT1B/1D receptor antagonist with pKi of 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptor. |
|
| DC11090 |
GR3027
Featured
|
GR3027 (Golexanolone) is a GABA-A receptor modulating steroid antagonist that selectively antagonizes the enhanced activation of GABAA receptors by neurosteroids such as allopregnanolone and THDOC. |
|
| DC21066 |
GR73632
Featured
|
GR-73632 is a potent and selective tachykinin NK1 receptor agonist with EC50 of 2 nM, promotes differentiation but not survival of rat chromaffin cells in vitro.. |
|
| DC9299 |
GRA Ex-25
Featured
|
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. |
|
| DC22629 |
GRL-0617
Featured
|
GRL-0617 is a potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 0.6 uM, Ki of 0.49 uM. |
|
| DC12579 |
GS-6207
Featured
|
GS-6207 (GS6207, GS-CA1) is a potent, selective inhibitor of HIV-1 capsid function with potency and potential to be clinically effective against a broad range of HIV-1 strains.. |
|
| DC7805 |
CID 121433863
Featured
|
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate. |
|
| DC9294 |
Tenofovir Alafenamide Hemifumarate
Featured
|
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate. |
|
| DC7138 |
GS-9620(Vesatolimod)
Featured
|
GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7(TLR-7) in chimpanzees with chronic HBV infection. |
|
| DC8006 |
GS967(GS-458967)
Featured
|
GS967 is a novel, potent, and selective inhibitor of cardiac late sodium current(late INa). |
|
| DC7626 |
GS9973（Entospletinib）
Featured
|
GS-9973 is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM. Phase 2. |
|
| DC23876 |
GSA-10
Featured
|
GSA-10 is a novel small-molecule positive modulator of Smoothened with EC50 of 1.2 uM in the differentiation assay. |
|
| DC5147 |
Molibresib (I-BET-762)
Featured
|
GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4). |
|
| DC8360 |
GSK 5959
Featured
|
GSK 5959 is a potent, cell-permeable inhibitor of the BRPF1 bromodomain (IC50 = 80 nM). |
|
| DC7654 |
GSK J4 HCl
Featured
|
GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. |
|
| DC1036 |
GSK-0660
Featured
|
GSK-0660 is a selective PPARδ antagonist (IC50 values are 0.155, > 10 and ≥ 10 μM at PPARδ, PPARα and PPARγ respectively). |
|
| DC11280 |
GSK1016790A
Featured
|
GSK1016790A is a novel and potent TRPV4 channel agonist. |
|
| DC7140 |
GSK1070916
Featured
|
GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM; displays >100-fold selectivity against the closely related Aurora A-TPX2 complex(IC50=490 nM). |
|
| DC7042 |
GSK-126
Featured
|
GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase with Ki value of 0.5 nM. |
|
| DC7422 |
GSK1292263
Featured
|
GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. |
|
| DC8766 |
GSK1324726A (I-BET726)
Featured
|
GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), and BRD4 (IC50= 22 nM). |
|
| DC8577 |
FFA4 (GPR120) agonist GSK137647A
Featured
|
GSK-137647 is a potent and selective FFA4 (GPR120) agonist (pEC50 values are 6.3, 6.2 and 6.1 at the human, mouse and rat receptor, respectively). Exhibits ≥100-fold selectivity against a panel of 61 targets including FFA1, FFA2 and FFA3. |
|
| DC9705 |
GSK163090
Featured
|
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively. |
|
| DC10124 |
GSK180736A
Featured
|
GSK180736A is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM. |
|
